How do you approach systemic treatment for endometrial endometrioid adenocarcinoma with neuroendocrine differentiation?

We treat these as endometrioid primary as the histologic diagnosis states, "endometrioid endometrial adenocarcinoma with neuroendocrine differentiation" instead of "primary neuroendocrine carcinoma of the uterus." Therefore, follow the literature from GOG 209 to support carboplatin/paclitaxel, especially if on complete hysterectomy specimen.

For primary poorly differentiated neuroendocrine carcinoma, we would offer cisplatin vs carboplatin/etoposide/atezolizumab regimen consistent with NCCN guide...